
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics Inc has demonstrated significant growth momentum, with an impressive increase in net revenue projections for 4Q, rising to $16.2 million from $4.5 million, supported by a robust 40% growth in unit prescriptions. The company reported 2,716 prescriptions in 3Q25 and further accelerated its performance in October with 2,189 prescriptions, exceeding the entire third quarter's volume within just seven weeks of 4Q25. Additionally, Pelthos is strategically expanding its sales force from 50 to 64 territory managers, aiming to increase coverage from approximately 8,000 to 10,000 clinicians, positioning itself favorably in a significant underlying market.
Bears say
Pelthos Therapeutics Inc faces a negative outlook due to several critical factors that could adversely affect its financial performance. The potential challenges in securing adequate reimbursement levels and market adoption among specialists may result in revenue growth lagging behind projections, especially if competition from alternative products increases and affects market share. Additionally, risks associated with funding shortages and operational execution deficiencies could hinder strategic initiatives and affect overall commercialization efforts, further exacerbating financial uncertainties.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares